Kura Oncology
KURA
148 hedge funds and large institutions have $795M invested in Kura Oncology in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 42 reducing their positions, and 22 closing their positions.
373% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $1.48M
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 42
5% more funds holding
Funds holding: 141 → 148 (+7)
4.45% less ownership
Funds ownership: 105.86% → 101.41% (-4.5%)
10% less capital invested
Capital invested by funds: $885M → $795M (-$90.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$15.9M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$11.9M |
| 3 |
AC
Armistice Capital
New York
|
+$10.5M |
| 4 |
DM
Deerfield Management
New York
|
+$10.1M |
| 5 |
BlackRock
New York
|
+$9.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$30M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.83M |
| 4 |
State Street
Boston,
Massachusetts
|
-$9.81M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.54M |
KURA Hedge Fund Activity: Q2 2023 in Review
148 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2023, worth a combined $795M — down 10% from $885M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KURA positions and 22 closed out — a net gain of 7 holders — while 50 added to existing stakes and 42 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $15.9M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $30M sold.
- 148 institutional investors held Kura Oncology (KURA) as of Q2 2023, up from 141 in Q1 2023.
- Funds reported $795M of Kura Oncology stock for Q2 2023, down 10% quarter-over-quarter.
- 29 funds opened new Kura Oncology positions in Q2 2023 and 22 closed out, a net change of +7 holders.
- The largest Kura Oncology buyer in Q2 2023 was Prosight Management, an estimated $15.9M added.
- The largest Kura Oncology seller in Q2 2023 was T. Rowe Price Investment Management, an estimated $30M sold.
Based on aggregated 13F filings for Q2 2023.